Marked radiographic response of a HER-2-overexpressing biliary cancer to trastuzumab

Abstract

Trastuzumab is a monoclonal antibody targeting HER-2. HER-2 overexpression has been described in gallbladder cancer and in cholangiocarcinoma. This report describes the first case of a patient with HER-2 overexpressing metastatic gallbladder adenocarcinoma and responding radiographically and biochemically to trastuzumab alone.

Keywords:

• metastatic gallbladder adenocarcinoma
• HER-2 overexpression
• trastuzumab

Disclosure

The author is on the Genentech speakers bureau for products other than trastuzumab. Otherwise, the author declares no relevant conflicts of interest in this work.